Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival
- 129 Downloads
Adjuvant radiotherapy (ART) for biochemical relapse (BR) after radical prostatectomy (RP) showed increased disease-free survival (DFS) in three previous randomized trials. Retrospective phase II trials evaluated if early salvage RT (ESRT) is equivalent to ART. Our study aims to compare ART and ESRT to salvage RT.
Materials and methods
We compared RP plus ART and ESRT versus SRT. Indication for RT was made by PSA determination after RP: ART when PSA ≤ 0.2 ng/ml, ESRT when PSA ≤ 0.3 after PSA rise from 0.0 to SRT PSA ≥ 0.3. The cause of death of each patients was analyzed, DFS, cause-specific survival (CSS) overall survival (OS) and metastasis-free survival (MFS) in relation to RT intention.
Between 1993 and 2008, 204 patients with a median age of 65 years (44–75) were treated. The median follow-up was 160 months (28.1–273.3). At diagnosis, 89.7% had localized clinical stages and 90.2% had Gleason (G) ≤ 7. The median PSA was 10 (range 4–101). The postoperative G was ≥ 7 in 66.2%; 56.4% had ≥ 2 positive margins; 29.4% received ART, 20% ESRT and 59.3% SRT. The DFS for ART, ESRT and SRT was 74, 56 and 39% with significant differences between the three groups (p < 0.001). ART + ESRT were combined versus SRT; for the DFS, the significant differences (p < 0.001) remained 67% versus 39%. Positive margins, pT3 and pre-RT PSA were significant factors on multivariate analysis. The CSS in the ART + ESRT group was 92 vs. 78% in the SRT group (p < 0.05). OS was 69% in ART + ESRT vs. 57% in SRT (p < 0.05). MFS was 82.7% in ART + ESRT vs. 67.4% in SRT.
In this study the ART + ESRT presented benefits versus SRT in DFS, CSS, OS and MFS.
KeywordsPostoperative radiotherapy Biochemical relapse Adjuvant radiotherapy Early salvage and salvage radiotherapy
To Donna Pringle for her English revision of this manuscript.
Compliance with ethical standards
Conflicts of interest
All the authors not have any conflicts of interest.
Research involving Human Participants and/or Animals it is not performed.
All the patients signed informed consent before postoperative radiotherapy.
- 1.Bolla M, van Poppel H, Tombal B, et al. Radiation oncology and genitourinary groups. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomized controlled trial (EORTC trial 22911). Lancet. 2012;380:2018–27. https://doi.org/10.1016/s0140-6736(12)61253-7.CrossRefGoogle Scholar
- 2.Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen. ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–30.CrossRefGoogle Scholar
- 5.Wu WJ, Potters L. Counterpoint: early salvage vs. adjuvant radiotherapy for high-risk prostate cancer. The data for adjuvant radiotherapy remain strong. Oncology. 2017;31:752–4.Google Scholar
- 15.Gandaglia G, Fossati N, Karnes RJ, et al. Use of concomitant androgen deprivation therapy in patient treated with early salvage radiotherapy for biochemical recurrence after radical prostatectomy: long term results from a large, multi-institutional series. Eur Urol. 2017;73:512–8.CrossRefGoogle Scholar